Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

被引：0
|
作者：
Michelle Treitel
Thomas Marbury
Richard A. Preston
Ilias Triantafyllou
William Feely
Edward O’Mara
Claudia Kasserra
Samir Gupta
Eric A. Hughes
机构：
[1] Merck Sharp & Dohme Corp.,Division of Clinical Pharmacology Research Unit, Miller School of Medicine
[2] Orlando Clinical Research Center,Merck Research Laboratories
[3] University of Miami,undefined
[4] Merck & Co.,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 9期
关键词：
Hepatic Impairment; Boceprevir; Severe Hepatic Impairment; Mild Hepatic Impairment; Median Tmax;
D O I：
10.1007/BF03261935
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 628
页数：9
相关论文
共 50 条
  • [21] Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
    Miyazawa, Y
    Blum, RA
    Schentag, JJ
    Kamimura, H
    Matsushima, H
    Swarz, H
    Ito, Y
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (09): : 603 - 621
  • [22] Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis
    Grasela, DM
    Stoltz, RR
    Barry, M
    Bone, M
    Mangold, B
    O'Grady, P
    Raymond, R
    Haworth, SJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) : 2149 - 2153
  • [23] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [24] Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
    Lawitz, Eric
    Parmar, Deven
    Momin, Taufik
    Shaikh, Farheen
    Patel, Harilal
    Hayes, Helen
    Swint, Kimberly
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (12): : 1142 - 1155
  • [25] Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function
    Wicha, Wolfgang W.
    Marbury, Thomas C.
    Dowell, James A.
    Crandon, Jared L.
    Leister, Cathie
    Ermer, James
    Gelone, Steven P.
    [J]. PHARMACOTHERAPY, 2021, 41 (05): : 457 - 462
  • [26] SINGLE-DOSE PHARMACOKINETICS OF BMS-790052 IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY SUBJECTS
    Bifano, Marc
    Sevinsky, Heather
    Persson, A.
    Chung, Ellen
    Wind-Rotolo, Megan
    Hwang, Carey
    Nettles, Richard
    Grasela, Dennis M.
    Marbury, Thomas C.
    DeMicco, Michael P.
    Bertz, Richard J.
    [J]. HEPATOLOGY, 2011, 54 : 1004A - 1004A
  • [27] Single-dose pharmacokinetics of methadone in healthy subjects
    Wolff, K
    Hay, AWM
    Shires, S
    Feely, M
    Calvert, R
    RostamiHodjegan, A
    Tucker, GT
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (05) : P670 - P670
  • [28] Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment
    Türck, D
    Weber, W
    Sigmund, R
    Budde, K
    Neumayer, HH
    Fritsche, L
    Rominger, KL
    Feifel, U
    Slowinski, T
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (02): : 163 - 172
  • [29] The multiple dose pharmacokinetics of cilansetron in subjects with normal and impaired hepatic function.
    Pardue, RL
    Zipfel, L
    Fritsch, H
    Brennan, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P78 - P78
  • [30] Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
    Kenneth C. Lasseter
    Ander Sologuren
    Anna La Noce
    Stacy C. Dilzer
    [J]. Clinical Drug Investigation, 2013, 33 : 665 - 673
12345